The January/February issue of NeuroPerspective has been released, and as is the annual tradition, it reviews 2017 and previews 2018. Over 80 companies have capsule summaries of important events and anticipations, including Acorda, Adamas, Alkahest, AgeneBio, Allergan, AveXis, Biogen, Biohaven, Blackthorn, Denali, Genentech, JNJ, Lilly, Lundbeck, Marinus, Minerva, Neuren, Neurocrine Biosciences, Newron, Perception, Pfizer, Roche, SAGE, Sunovion, Teva, Trevena, United Neuroscience, Voyager Therapeutics, Wave Life Sciences, Xenon, Zogenix, and fifty more.
Highlights and Lowlights from 2017 are assessed, with particular consideration of Scott Gottlieb’s tenure at the FDA; new GABAergic programs for depression (e.g. SAGE and Marinus); Roche‘s savvy strategy with Ocrevus; the impending revolution in migraine treatment as the CGRP system comes into its own as a target (Amgen/Novartis, Teva, Lilly, Alder, Allergan, Biohaven); the Opioid Epidemic and the slow-to-emerge shift in regulatory tactics to address it; the Gut-Brain Microbiome; Progress in BBB delivery technologies (e.g. BiOasis, Armagen, Roche/Genentech, Denali). Trends in neuroscience funding and partnering are examined, as is the sad debacle that was Dart Neuroscience; Brent Saunders (Allergan) and his oscillation from paragon to parody; and our consideration of whether aducanumab is going to be ‘déja vu all over again.’
This issue also includes a guest article from Joel Sanders PhD (Defined Health/Cello Health), who takes his lengthy experience in assessing the field of immunooncology and turns it to CNS, in ‘The Rise of Neuroimmunology.’ The Company Spotlight covers NMDA specialist Aptinyx.
